The JV will establish a state-of-the-art manufacturing facility to manufacture fermented animal free protein to cater to the global markets
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Stringent regulatory environments can make OEMs reluctant to change processes and materials for approved medical devices
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Morepen Labs successfully raised Rs. 200 Crore through QIP
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Subscribe To Our Newsletter & Stay Updated
